Intellia Therapeutics Inc (NTLA)
EBITDA Margin
-656.03%
TTM · Period ending:
NTLA EBITDA Margin
Latest reported-656.03%period ending
Latest reported-656.03%period ending
NTLA TTM EBITDA Margin (-326.76% → -656.03%)
TTM ebitda margin
High-resolution chart · PNG
NTLA ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| -656.0313% | |
| -581.9267% | |
| -594.655% | |
| -753.2541% | |
| -889.2824% | |
| -1,131.5653% | |
| -878.9951% | |
| -1,188.5508% | |
| -1,085.4069% | |
| -904.9958% | |
| -1,301.7671% | |
| -876.8415% | |
| -839.4615% | |
| -790.2235% | |
| -895.2514% | |
| -845.4827% | |
| -867.1681% | |
| -954.8468% | |
| -790.3095% | |
| -831.0107% | |
| -428.8519% | |
| -278.7085% | |
| -224.6301% | |
| -188.7591% | |
| -226.8987% | |
| -240.7801% | |
| -233.7749% | |
| -229.9673% | |
| -247.2841% | |
| -261.9828% | |
| -283.9127% | |
| -310.6187% | |
| -284.6006% | |
| -276.5372% | |
| -254.857% | |
| -211.7403% | |
| -200.8264% | |
| -176.1056% | |
| -188.452% | |
| -207.23% | |
| -232.4861% | |
| -281.9587% | |
| -216.4295% | |
| -273.6497% | |
| -326.7555% |